Aliskiren: A Novel Renin Inhibitor for Hypertension

Author(s): Vandana Tayal, Bhupinder Singh Kalra

Journal Name: Current Drug Therapy

Volume 2 , Issue 3 , 2007

Become EABM
Become Reviewer


Hypertension is one of the major causes of cardiovascular morbidity. Most patients who are on treatment for hypertension fail to achieve adequate control with the existing therapy and rates of cardiovascular morbidity remain high. As the renin-angiotensin-aldosterone system is strongly implicated in the development of hypertension-related target organ damage, intensive efforts have been devoted towards the development of drugs targeting this system. In addition to angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), inhibition of renin has also become a clinical reality. Aliskiren, a novel renin inhibitor, has overcome a number of shortcomings of existing drugs and is now available to address angiotensin production directly at its rate-limiting step.

Keywords: Renin inhibitor, SPP100, aliskiren, hypertension

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2007
Page: [236 - 239]
Pages: 4
DOI: 10.2174/157488507781695667
Price: $65

Article Metrics

PDF: 5